Deutsch English Français

Contact

EP2935318

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP2935318

EP2935318 - NOVEL GLP-1 RECEPTOR AGONISTS WITH CHOLESTEROL EFFLUX ACTIVITY [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 21.04.2017 Database last updated on 24.04.2024
Former	Examination is in progress Status updated on 19.01.2017
Most recent event Tooltip	21.04.2017	Application deemed to be withdrawn	published on 24.05.2017 [2017/21]
Applicant(s)	For all designated states Novo Nordisk A/S Novo Allé 2880 Bagsværd / DK
	[2015/44]
Inventor(s)	01 / THØGERSEN, Henning Novo Nordisk A/S Novo Allé 2880 Bagsværd / DK
	02 / TORNØE, Christian Wenzel Novo Nordisk A/S Novo Allé 2880 Bagsværd / DK
	03 / ROLIN, Bidda Charlotte Novo Nordisk A/S Novo Allé 2880 Bagsværd / DK
	04 / KODRA, János Tibor Novo Nordisk A/S Novo Allé 2880 Bagsværd / DK
	05 / RASMUSSEN, Salka Elbøl Novo Nordisk A/S Novo Allé 2880 Bagsværd / DK
	06 / LAU, Jesper Novo Nordisk A/S Novo Allé 2880 Bagsværd / DK
	[2015/44]
Application number, filing date	13818736.4	19.12.2013
	[2015/44]
	WO2013EP77357
Priority number, date	EP20120198295	19.12.2012 Original published format: EP 12198295
	US201261740469P	21.12.2012 Original published format: US 201261740469 P
	[2015/44]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2014096179
	Date:	26.06.2014
	Language:	EN
	[2014/26]
	Type:	A1 Application with search report
	No.:	EP2935318
	Date:	28.10.2015
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 26.06.2014 takes the place of the publication of the European patent application.
	[2015/44]
Search report(s)	International search report - published on:	EP	26.06.2014
Classification	IPC:	C07K14/605	[2015/44]
	CPC:	C07K14/605 (EP,US); A61P29/00 (EP); A61P3/06 (EP); A61P3/10 (EP); A61P43/00 (EP); A61P9/00 (EP); (+) A61P9/10 (EP); A61P9/12 (EP) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/44]
Title	German:	NEUARTIGE GLP-1-REZEPTORAGONISTEN MIT CHOLESTERINEFFLUXWIRKUNG	[2015/44]
	English:	NOVEL GLP-1 RECEPTOR AGONISTS WITH CHOLESTEROL EFFLUX ACTIVITY	[2015/44]
	French:	NOUVEAUX AGONISTES DES RÉCEPTEURS À LA GLP-1 AVEC ACTIVITÉ D'EFFLUX DU CHOLESTÉROL	[2015/44]
Entry into regional phase	20.07.2015	National basic fee paid
	20.07.2015	Designation fee(s) paid
	20.07.2015	Examination fee paid
Examination procedure	20.07.2015	Examination requested [2015/44]
	04.02.2016	Amendment by applicant (claims and/or description)
	14.06.2016	Despatch of a communication from the examining division (Time limit: M06)
	03.01.2017	Application deemed to be withdrawn, date of legal effect [2017/21]
	20.01.2017	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2017/21]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 14.06.2016
Fees paid	Renewal fee
	04.01.2016	Renewal fee patent year 03
	02.01.2017	Renewal fee patent year 04
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[XY]WO2008101017 (INDIANA UNVERSITY RES AND TECH [US], et al) [X] 8,10 * sequences 500-501, 494-495, 488-489 * [Y] 1-7,9,11-19;
		[XY]EP1359159 (SOD CONSEILS RECH APPLIC [FR]) [X] 8,10 * paragraph [0006] * [Y] 1-7,9,11-19;
		[X]WO9929336 (LILLY CO ELI [US], et al) [X] 7 * sequence 1 *;
		[X]WO2011088837 (ZEALAND PHARMA AS [DK], et al) [X] 7 * sequences 154, 200 *;
		[X]WO03011892 (US GOV HEALTH & HUMAN SERV [US], et al) [X] 7 * sequence 11 *;
		[Y]US2005202532 (BIELICKI JOHN K [US], et al) [Y] 1-19 * paragraph [0009] *;
		[XPY]WO2013164483 (ZEALAND PHARMA AS [DK]) [XP] 7 * sequence 27 * [Y] 1-6,8-19;
		[X]WO2011136361 (SANWA KAGAKU KENKYUSHO CO [JP], et al) [X] 7 * sequence 32 *;
		[X]WO2010096052 (MERCK SHARP & DOHME [US], et al) [X] 7 * sequence 57 *;
		[X]WO2011134471 (ZEALAND PHARMA AS [DK], et al) [X] 7 * sequence 71 *
		[Y] - S. RUNGE ET AL, "Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain", JOURNAL OF BIOLOGICAL CHEMISTRY, (20080303), vol. 283, no. 17, doi:10.1074/jbc.M708740200, ISSN 0021-9258, pages 11340 - 11347, XP055060531 [Y] 1-19 * page 11340, column l, lines 15-17, 18-20; figure 2 * * page 11343, column l, lines 1-4, 14-16 * * page 11343, column r, lines 43-45 * DOI: http://dx.doi.org/10.1074/jbc.M708740200
		[Y] - C. R. UNDERWOOD ET AL, "Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor", JOURNAL OF BIOLOGICAL CHEMISTRY, (20100101), vol. 285, no. 1, doi:10.1074/jbc.M109.033829, ISSN 0021-9258, pages 723 - 730, XP055060541 [Y] 1-19 * page 723, column l, line 19 * * page 724, column l, paragraphs 2-3 * DOI: http://dx.doi.org/10.1074/jbc.M109.033829
		[XY] - J. Z. DONG ET AL, "Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes", DIABETES, OBESITY AND METABOLISM, (20110101), vol. 13, no. 1, doi:10.1111/j.1463-1326.2010.01313.x, ISSN 1462-8902, pages 19 - 25, XP055049098 [X] 8,10 * page 20, column l, lines 17-20, 26-29, 29-32 * [Y] 1-7,9,11-19 DOI: http://dx.doi.org/10.1111/j.1463-1326.2010.01313.x
		[Y] - MICHAEL H DAVIDSON, "Cardiovascular Effects of Glucagonlike peptide 1 Agonists", AMERICAN JOURNAL OF CARDIOLOGY, vol. 108, no. 3, doi:10.1016/J.AMJCARD.2011.03.046, ISSN 0002-9149, (2011), pages 33B - 41B, (20110401), XP028249081 [Y] 1-19 * figure 2; table 1 * DOI: http://dx.doi.org/10.1016/j.amjcard.2011.03.046
		[Y] - "Therapeutic isolated polypeptide, SEQ ID 4.", Geneseq, (20081127), Database accession no. ATO06830, URL: EBI, XP002696081 [Y] 1-19 * sequence . *
		[Y] - "Lecithin:cholesterol acyltransferase activation exhibiting peptide #243.", Geneseq, (19990709), Database accession no. AAY18918, URL: EBI, XP002696082 [Y] 1-19 * sequence . *
		[Y] - "Lecithin:cholesterol acyltransferase activation exhibiting peptide #4.", Geneseq, (19990709), Database accession no. AAY18683, URL: EBI, XP002696083 [Y] 1-19 * sequence . *
		[Y] - "Lipid efflux promoting peptide sequence, SEQ ID 338.", Geneseq, (20080515), Database accession no. AOG45030, URL: EBI, XP002696084 [Y] 1-19 * sequence . *
		[Y] - "N965-8 peptide with ABCA cholesterol efflux activity, SEQ:2.", Geneseq, (20100401), Database accession no. AXV23883, URL: EBI, XP002696085 [Y] 1-19 * sequence . *
		[Y] - DAN DONNELLY, "The structure and function of the glucagon-like peptide-1 receptor and its ligands", BRITISH JOURNAL OF PHARMACOLOGY, (20120501), vol. 166, no. 1, doi:10.1111/j.1476-5381.2011.01687.x, ISSN 0007-1188, pages 27 - 41, XP055060540 [Y] 1-19 * figure 3 * DOI: http://dx.doi.org/10.1111/j.1476-5381.2011.01687.x
		[I] - J. K. BIELICKI ET AL, "A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice", THE JOURNAL OF LIPID RESEARCH, (20100601), vol. 51, no. 6, doi:10.1194/jlr.M003665, ISSN 0022-2275, pages 1496 - 1503, XP055071388 [I] 1-19 * page 1498, column r, lines 1-11; figures 1, 2 * DOI: http://dx.doi.org/10.1194/jlr.M003665
		[Y] - EPAND ET AL, "The amphipathic helix: its possible role in the interaction of glucagon and other peptide hormones with membrane receptor sites", TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER, HAYWARDS, GB, vol. 8, no. 6, doi:10.1016/0968-0004(83)90212-8, ISSN 0968-0004, (19830601), pages 205 - 207, (19830601), XP023569664 [Y] 1-19 * page 205, column m, line 26 - column r, line 13 * * page 206, column l, paragraph 2 - column r, paragraph 1 * DOI: http://dx.doi.org/10.1016/0968-0004(83)90212-8

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p